BioSpace News Archive

Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47 th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) -Abstract will be shared at Presidential Symposium and featured in this year’s “Live with Best Abstracts” session-

Roche – the leader in personalized medicine and the world’s greatest biotechnological company – provides end-to-end integral and strategic solutions to the Roche Pharmaceutical and Diagnostic divisions all over the Americas in areas such as finance, People & Culture, purchasing, and information technologies.

Resverlogix Corp. (“Resverlogix”) (TSX:RVX) announced today the publishing of a new article titled: “Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro”, on the pre-print server, bioRxiv.

Mr. Dolban has been involved in new business development for over 25 years and is currently focusing his experience into resource-based sectors.

The Company’s Assembling of this Sales Force Coincides with Launch of its Increased Tauri-Gum™ CBD & CBG Infusion Concentrations (25mg/per Serving)

Also, effective April 5, 2021, Robert Thast has resigned from his position as President and Chief Executive Officer and will remain a Director and Special Advisor to Izotropic.

HTX Urology in Webster, TX (www.htxurology.com) is participating in an FDA cleared research study for a new, minimally invasive device pioneered by Urotronic, Inc., that could dramatically change the way millions of men with enlarged prostates are treated.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

United Network for Organ Sharing (UNOS), the nonprofit managing the nation’s organ transplant system, is partnering with the Virginia Modeling, Analysis & Simulation Center (VMASC) at Old Dominion University to develop a series of simulation models to examine the impact of possible changes to the transplant ecosystem.

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today the enrollment of the first patient in a pilot study of the Pure-Vu® System.